We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Bioprocessing Antibody Drug Conjugates in Biopharma: Making Magic Bullets

Article   Mar 28, 2017 | Original Article by Adam Tozer Ph.D

 
Bioprocessing Antibody Drug Conjugates in Biopharma: Making Magic Bullets

ADCs are the next generation of cancer therapies. Credit: Lonza

 
 
 

RELATED ARTICLES

Advanced Data Analytics in Pharma: Going Beyond Patterns to Understand the “Why”

Article

New developments in pharmaceuticals have made new drugs and treatments available, enhancing options and quality of life for patients. Advanced data analytics solutions mean treatments are more effective and affordable, and less intrusive. However, these evolutions will mean major changes in how companies interact with patients and caregivers, and this will necessitate new capabilities for operations and supply chain.

READ MORE

Antimicrobial Resistance – the Rise of Global Superbugs

Article

Antimicrobials have revolutionized medicine by enabling treatments for diseases that would once have proven fatal, however,they have since proven to be a double-edged sword.

READ MORE

How Can We Make Behavioral Science More Reproducible?

Article

A scientist explains how, by making 'stock' behavioral tasks more accurate, we can improve reproducibility.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE